Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8649292rdf:typepubmed:Citationlld:pubmed
pubmed-article:8649292lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C0026918lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:8649292lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:8649292pubmed:issue9lld:pubmed
pubmed-article:8649292pubmed:dateCreated1996-7-19lld:pubmed
pubmed-article:8649292pubmed:abstractTextAbout one in three patients with advanced immune deficiency will develop disseminated MAC infection. This incidence can be reduced with prophylactic drug therapy, and established infections can be effectively treated, with improved quality of life and lengthened survival.lld:pubmed
pubmed-article:8649292pubmed:languageenglld:pubmed
pubmed-article:8649292pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8649292pubmed:citationSubsetIMlld:pubmed
pubmed-article:8649292pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8649292pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8649292pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8649292pubmed:statusMEDLINElld:pubmed
pubmed-article:8649292pubmed:monthMaylld:pubmed
pubmed-article:8649292pubmed:issn0025-729Xlld:pubmed
pubmed-article:8649292pubmed:authorpubmed-author:MarriottDDlld:pubmed
pubmed-article:8649292pubmed:authorpubmed-author:GottliebTTlld:pubmed
pubmed-article:8649292pubmed:authorpubmed-author:DayG WGWlld:pubmed
pubmed-article:8649292pubmed:issnTypePrintlld:pubmed
pubmed-article:8649292pubmed:day6lld:pubmed
pubmed-article:8649292pubmed:volume164lld:pubmed
pubmed-article:8649292pubmed:ownerNLMlld:pubmed
pubmed-article:8649292pubmed:authorsCompleteYlld:pubmed
pubmed-article:8649292pubmed:pagination543-5lld:pubmed
pubmed-article:8649292pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:meshHeadingpubmed-meshheading:8649292-...lld:pubmed
pubmed-article:8649292pubmed:year1996lld:pubmed
pubmed-article:8649292pubmed:articleTitleManaging HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection.lld:pubmed
pubmed-article:8649292pubmed:affiliationFairfield Hospital, Melbourne, VIC.lld:pubmed
pubmed-article:8649292pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8649292pubmed:publicationTypeReviewlld:pubmed